Details of the Drug

General Information of Drug (ID: DMXKJ6C)

• Drug Name: Torasemide
• Synonyms: Demadex; Dilutol; Luprac; Presoril; Sutril; TORSEMIDE; Toradiur; Torasemida; Torasemidum; Torem; Torocard; Torrem; Unat; Torasemide N; Torsemide [USAN]; AC 4464; BM 02015; JDL 464; BM-02015; Demadex (TN); Demadex, Torsemide; GJ-1090; JDL-464; KS-1123; Luprac (TN); PW-2132; Torasemida [INN-Spanish]; Torasemidum [INN-Latin]; Torsemide (USP); Torasemide (JAN/INN); N-(Isopropylcarbamoyl)-4-(m-tolylamino)pyridine-3-sulfonamide; N-{[(1-methylethyl)amino]carbonyl}-4-[(3-methylphenyl)amino]pyridine-3-sulfonamide; N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide; 1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea; 1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea; 1-isopropyl-3-((4-(3-methylphenylamino)pyridine)-3-sulfonyl)urea; 1-isopropyl-3-[(4-m-toluidino-3-pyridyl) sulfonyl]urea

Indication

Disease Entry	ICD 11	Status	REF
Congestive heart failure	BD10	Approved	[1]
Edema	MG29	Approved	[2]
Renal hypoplasia	N.A.	Approved	[3]

• Therapeutic Class: Diuretics
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 348.4
  Logarithm of the Partition Coefficient (xlogp); 2.7
  Rotatable Bond Count (rotbonds); 5
  Hydrogen Bond Donor Count (hbonddonor); 3
  Hydrogen Bond Acceptor Count (hbondacc); 5
• ADMET Property:
  Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 2213 mcgh/L [4]
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 6 h [4]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [5]
  Bioavailability: The bioavailability of drug is 80% [4]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 0.53 mL/min/kg [6]
  Elimination: Torasemide is mainly hepatically processed and excreted in the feces from which about 70-80% of the administered dose is excreted by this pathway [7]
  Half-life: The concentration or amount of drug in body reduced by one-half in 3.5 hours [8]
  Metabolism: The drug is metabolized via the liver [9]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 9.55724 micromolar/kg/day [10]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.01% [6]
  Vd: The volume of distribution (Vd) of drug is 0.2 L/kg [9]
  Water Solubility: The ability of drug to dissolve in water is measured as 0.16 mg/mL [5]
• Chemical Identifiers:
  Formula: C16H20N4O3S
  IUPAC Name: 1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea
  Canonical SMILES: CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C
  InChI: InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)
  InChIKey: NGBFQHCMQULJNZ-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 41781
  ChEBI ID: CHEBI:9637
  CAS Number: 56211-40-6
  DrugBank ID: DB00214
  TTD ID: D0J9XZ
  VARIDT ID: DR00222
  INTEDE ID: DR1620
  ACDINA ID: D00692
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Solute carrier family 12 member 1 (SLC12A1)	TTS087L	S12A1_HUMAN	Blocker	[11]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[12]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2C9 (CYP2C9) Main DME	DE5IED8	CP2C9_HUMAN	Substrate	[13]
Cytochrome P450 2C8 (CYP2C8) Main DME	DES5XRU	CP2C8_HUMAN	Substrate	[14]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 2C9 (CYP2C9)	OTGLBN29	CP2C9_HUMAN	Biotransformations	[15]
Solute carrier family 12 member 2 (SLC12A2)	OT3ZJ3LH	S12A2_HUMAN	Gene/Protein Processing	[16]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Torasemide

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Carvedilol	DMHTEAO	Moderate	Increased risk of ventricular arrhythmias by the combination of Torasemide and Carvedilol.	Heart failure [BD10-BD1Z]	[17]
Chlorothiazide	DMLHESP	Moderate	Increased risk of fluid/electrolyte loss by the combination of Torasemide and Chlorothiazide.	Heart failure [BD10-BD1Z]	[18]
Digoxin	DMQCTIH	Moderate	Increased risk of hypomagnesemia by the combination of Torasemide and Digoxin.	Heart failure [BD10-BD1Z]	[19]
Hydroflumethiazide	DMVPUQI	Moderate	Increased risk of fluid/electrolyte loss by the combination of Torasemide and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[18]
Digitoxin	DMWVIGP	Moderate	Increased risk of hypokalemia by the combination of Torasemide and Digitoxin.	Heart failure [BD10-BD1Z]	[19]

Coadministration of a Drug Treating the Disease Different from Torasemide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Cefuroxime	DMSIMD8	Moderate	Increased renal excretion of Torasemide caused by Cefuroxime.	Acute bronchitis [CA42]	[20]
Arn-509	DMT81LZ	Moderate	Accelerated clearance of Torasemide due to the transporter induction by Arn-509.	Acute myeloid leukaemia [2A60]	[21]
Framycetin	DMF8DNE	Major	Increased risk of ototoxicity by the combination of Torasemide and Framycetin.	Alcoholic liver disease [DB94]	[22]
Oxandrolone	DMU9MYJ	Moderate	Decreased metabolism of Torasemide caused by Oxandrolone mediated inhibition of CYP450 enzyme.	Alcoholic liver disease [DB94]	[23]
Metronidazole	DMTIVEN	Moderate	Decreased metabolism of Torasemide caused by Metronidazole mediated inhibition of CYP450 enzyme.	Amoebiasis [1A36]	[23]
Cefamandole	DMNEXZF	Moderate	Increased renal excretion of Torasemide caused by Cefamandole.	Anaerobic bacterial infection [1A00-1A09]	[20]
Dronedarone	DMA8FS5	Major	Increased risk of ventricular arrhythmias by the combination of Torasemide and Dronedarone.	Angina pectoris [BA40]	[24]
Promazine	DMZAL7W	Moderate	Increased risk of ventricular arrhythmias by the combination of Torasemide and Promazine.	Appearance/behaviour symptom [MB23]	[25]
Voriconazole	DMAOL2S	Moderate	Decreased metabolism of Torasemide caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[23]
Zafirlukast	DMHNQOG	Moderate	Decreased metabolism of Torasemide caused by Zafirlukast mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[23]
Cefotetan	DM07TX3	Moderate	Increased renal excretion of Torasemide caused by Cefotetan.	Bacterial infection [1A00-1C4Z]	[20]
Kanamycin	DM2DMPO	Major	Increased risk of ototoxicity by the combination of Torasemide and Kanamycin.	Bacterial infection [1A00-1C4Z]	[22]
Ceftizoxime	DM3VOGS	Moderate	Increased renal excretion of Torasemide caused by Ceftizoxime.	Bacterial infection [1A00-1C4Z]	[20]
Ceftazidime	DM41GRA	Moderate	Increased renal excretion of Torasemide caused by Ceftazidime.	Bacterial infection [1A00-1C4Z]	[20]
Cefmetazole	DM42W1B	Moderate	Increased renal excretion of Torasemide caused by Cefmetazole.	Bacterial infection [1A00-1C4Z]	[20]
Loracarbef	DM4L8H3	Moderate	Increased renal excretion of Torasemide caused by Loracarbef.	Bacterial infection [1A00-1C4Z]	[20]
Cefoperazone	DM53PV8	Moderate	Increased renal excretion of Torasemide caused by Cefoperazone.	Bacterial infection [1A00-1C4Z]	[20]
Amikacin	DM5PDRB	Major	Increased risk of nephrotoxicity by the combination of Torasemide and Amikacin.	Bacterial infection [1A00-1C4Z]	[22]
Cefprozil	DM7DSYP	Moderate	Increased renal excretion of Torasemide caused by Cefprozil.	Bacterial infection [1A00-1C4Z]	[20]
Sulfamethoxazole	DMB08GE	Moderate	Decreased metabolism of Torasemide caused by Sulfamethoxazole mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[23]
Ceftriaxone	DMCEW64	Moderate	Increased renal excretion of Torasemide caused by Ceftriaxone.	Bacterial infection [1A00-1C4Z]	[20]
Cephalexin	DMD5JU8	Moderate	Increased renal excretion of Torasemide caused by Cephalexin.	Bacterial infection [1A00-1C4Z]	[20]
Streptomycin	DME1LQN	Major	Increased risk of nephrotoxicity by the combination of Torasemide and Streptomycin.	Bacterial infection [1A00-1C4Z]	[22]
Linezolid	DMGFPU2	Moderate	Additive hypotensive effects by the combination of Torasemide and Linezolid.	Bacterial infection [1A00-1C4Z]	[26]
Cefepime	DMHVWIK	Moderate	Increased renal excretion of Torasemide caused by Cefepime.	Bacterial infection [1A00-1C4Z]	[20]
Cefdinir	DMJ7A0H	Moderate	Increased renal excretion of Torasemide caused by Cefdinir.	Bacterial infection [1A00-1C4Z]	[20]
Cefpodoxime	DMJUNY5	Moderate	Increased renal excretion of Torasemide caused by Cefpodoxime.	Bacterial infection [1A00-1C4Z]	[20]
Cefaclor	DMJXDGC	Moderate	Increased renal excretion of Torasemide caused by Cefaclor.	Bacterial infection [1A00-1C4Z]	[20]
Gentamicin	DMKINJO	Major	Increased risk of nephrotoxicity by the combination of Torasemide and Gentamicin.	Bacterial infection [1A00-1C4Z]	[22]
Cefadroxil	DMMC345	Moderate	Increased renal excretion of Torasemide caused by Cefadroxil.	Bacterial infection [1A00-1C4Z]	[20]
Cefotaxime	DMEB837	Moderate	Increased renal excretion of Torasemide caused by Cefotaxime.	Bacterial infection [1A00-1C4Z]	[20]
Rabeprazole	DMMZXIW	Moderate	Increased risk of hypomagnesemia by the combination of Torasemide and Rabeprazole.	Bacterial infection [1A00-1C4Z]	[27]
Cefazolin	DMPDYFR	Moderate	Increased renal excretion of Torasemide caused by Cefazolin.	Bacterial infection [1A00-1C4Z]	[20]
Netilmicin	DMRD1QK	Major	Increased risk of ototoxicity by the combination of Torasemide and Netilmicin.	Bacterial infection [1A00-1C4Z]	[22]
Cefditoren	DMSUVM1	Moderate	Increased renal excretion of Torasemide caused by Cefditoren.	Bacterial infection [1A00-1C4Z]	[20]
Cefonicid	DMTX2BH	Moderate	Increased renal excretion of Torasemide caused by Cefonicid.	Bacterial infection [1A00-1C4Z]	[20]
Tobramycin	DMUI0CH	Major	Increased risk of nephrotoxicity by the combination of Torasemide and Tobramycin.	Bacterial infection [1A00-1C4Z]	[22]
Cefradine	DMUNSWV	Moderate	Increased renal excretion of Torasemide caused by Cefradine.	Bacterial infection [1A00-1C4Z]	[20]
Cefalotin	DMVYSLE	Moderate	Increased renal excretion of Torasemide caused by Cefalotin.	Bacterial infection [1A00-1C4Z]	[20]
Cefixime	DMY60I8	Moderate	Increased renal excretion of Torasemide caused by Cefixime.	Bacterial infection [1A00-1C4Z]	[20]
Cefoxitin	DMY8NC4	Moderate	Increased renal excretion of Torasemide caused by Cefoxitin.	Bacterial infection [1A00-1C4Z]	[20]
Vismodegib	DM5IXKQ	Moderate	Decreased metabolism of Torasemide caused by Vismodegib mediated inhibition of CYP450 enzyme.	Basal cell carcinoma [2C32]	[23]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Torasemide and Cariprazine.	Bipolar disorder [6A60]	[28]
Etidronic acid	DM1XHYJ	Moderate	Increased risk of hypocalcemia by the combination of Torasemide and Etidronic acid.	Bone paget disease [FB85]	[29]
Risedronate	DM5FLTY	Moderate	Increased risk of hypocalcemia by the combination of Torasemide and Risedronate.	Bone paget disease [FB85]	[29]
Alendronate	DMY2KX9	Moderate	Increased risk of hypocalcemia by the combination of Torasemide and Alendronate.	Bone paget disease [FB85]	[29]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Torasemide caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[30]
Toremifene	DMQYUWG	Moderate	Decreased metabolism of Torasemide caused by Toremifene mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[23]
Ceftibuten	DMWV2AG	Moderate	Increased renal excretion of Torasemide caused by Ceftibuten.	Bronchitis [CA20]	[20]
Sotalol	DML60TN	Moderate	Increased risk of ventricular arrhythmias by the combination of Torasemide and Sotalol.	Cardiac arrhythmia [BC9Z]	[17]
Phenylbutazone	DMAYL0T	Moderate	Antagonize the effect of Torasemide when combined with Phenylbutazone.	Chronic pain [MG30]	[31]
Ketoprofen	DMRKXPT	Moderate	Antagonize the effect of Torasemide when combined with Ketoprofen.	Chronic pain [MG30]	[31]
Levomilnacipran	DMV26S8	Moderate	Increased risk of hyponatremia by the combination of Torasemide and Levomilnacipran.	Chronic pain [MG30]	[32]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Torasemide caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[33]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Torasemide caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[23]
MK-8228	DMOB58Q	Moderate	Increased metabolism of Torasemide caused by MK-8228 mediated induction of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[34]
Sertraline	DM0FB1J	Moderate	Increased risk of hyponatremia by the combination of Torasemide and Sertraline.	Depression [6A70-6A7Z]	[32]
Fluoxetine	DM3PD2C	Moderate	Increased risk of hyponatremia by the combination of Torasemide and Fluoxetine.	Depression [6A70-6A7Z]	[32]
Vilazodone	DM4LECQ	Moderate	Increased risk of hyponatremia by the combination of Torasemide and Vilazodone.	Depression [6A70-6A7Z]	[32]
Paroxetine	DM5PVQE	Moderate	Increased risk of hyponatremia by the combination of Torasemide and Paroxetine.	Depression [6A70-6A7Z]	[32]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Torasemide and Selegiline.	Depression [6A70-6A7Z]	[26]
Vortioxetine	DM6F1PU	Moderate	Increased risk of hyponatremia by the combination of Torasemide and Vortioxetine.	Depression [6A70-6A7Z]	[32]
Duloxetine	DM9BI7M	Moderate	Increased risk of hyponatremia by the combination of Torasemide and Duloxetine.	Depression [6A70-6A7Z]	[32]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Torasemide and Isocarboxazid.	Depression [6A70-6A7Z]	[26]
Milnacipran	DMBFE74	Moderate	Increased risk of hyponatremia by the combination of Torasemide and Milnacipran.	Depression [6A70-6A7Z]	[32]
Escitalopram	DMFK9HG	Moderate	Increased risk of hyponatremia by the combination of Torasemide and Escitalopram.	Depression [6A70-6A7Z]	[32]
Tranylcypromine	DMGB5RE	Moderate	Additive hypotensive effects by the combination of Torasemide and Tranylcypromine.	Depression [6A70-6A7Z]	[26]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of hyponatremia by the combination of Torasemide and Desvenlafaxine.	Depression [6A70-6A7Z]	[32]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Torasemide and OPC-34712.	Depression [6A70-6A7Z]	[28]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Torasemide and Phenelzine.	Depression [6A70-6A7Z]	[26]
Venlafaxine	DMR6QH0	Moderate	Increased risk of hyponatremia by the combination of Torasemide and Venlafaxine.	Depression [6A70-6A7Z]	[32]
Citalopram derivative 1	DMITX1G	Moderate	Increased risk of hyponatremia by the combination of Torasemide and Citalopram derivative 1.	Discovery agent [N.A.]	[32]
Valproate	DMCFE9I	Moderate	Decreased metabolism of Torasemide caused by Valproate mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[23]
Eslicarbazepine	DMZREFQ	Moderate	Increased risk of hyponatremia by the combination of Torasemide and Eslicarbazepine.	Epilepsy/seizure [8A61-8A6Z]	[35]
Timolol	DM3NXRU	Moderate	Increased risk of hypertriglyceridemia by the combination of Torasemide and Timolol.	Essential hypertension [BA00]	[17]
Bendroflumethiazide	DM7EVLC	Moderate	Increased risk of fluid/electrolyte loss by the combination of Torasemide and Bendroflumethiazide.	Essential hypertension [BA00]	[18]
Benzthiazide	DMQWZ0H	Moderate	Increased risk of fluid/electrolyte loss by the combination of Torasemide and Benzthiazide.	Essential hypertension [BA00]	[36]
Nadolol	DMW6GVL	Moderate	Increased risk of hyperglycemia by the combination of Torasemide and Nadolol.	Essential hypertension [BA00]	[17]
Mefenamic acid	DMK7HFI	Moderate	Antagonize the effect of Torasemide when combined with Mefenamic acid.	Female pelvic pain [GA34]	[31]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Torasemide caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[23]
Dexlansoprazole	DM1DBV5	Moderate	Increased risk of hypomagnesemia by the combination of Torasemide and Dexlansoprazole.	Gastro-oesophageal reflux disease [DA22]	[27]
Omeprazole	DM471KJ	Moderate	Increased risk of hypomagnesemia by the combination of Torasemide and Omeprazole.	Gastro-oesophageal reflux disease [DA22]	[27]
Cisapride	DMY7PED	Major	Increased risk of ventricular arrhythmias by the combination of Torasemide and Cisapride.	Gastro-oesophageal reflux disease [DA22]	[37]
Carteolol	DMFMDOB	Moderate	Increased risk of hyperglycemia by the combination of Torasemide and Carteolol.	Glaucoma [9C61]	[17]
Metipranolol	DMJMVKI	Moderate	Increased risk of hyperglycemia by the combination of Torasemide and Metipranolol.	Glaucoma [9C61]	[17]
Levobetaxolol	DMSREPX	Moderate	Increased risk of hyperglycemia by the combination of Torasemide and Levobetaxolol.	Glaucoma [9C61]	[17]
Levobunolol	DMTNFCQ	Moderate	Increased risk of hypertriglyceridemia by the combination of Torasemide and Levobunolol.	Glaucoma [9C61]	[17]
Sulfinpyrazone	DMEV954	Moderate	Decreased metabolism of Torasemide caused by Sulfinpyrazone mediated inhibition of CYP450 enzyme.	Gout [FA25]	[23]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Torasemide caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[38]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Torasemide and Procarbazine.	Hodgkin lymphoma [2B30]	[26]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Torasemide caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Efavirenz	DMC0GSJ	Moderate	Decreased metabolism of Torasemide caused by Efavirenz mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Ritonavir	DMU764S	Minor	Increased metabolism of Torasemide caused by Ritonavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[39]
Fluvastatin	DM4MDJY	Moderate	Decreased metabolism of Torasemide caused by Fluvastatin mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[21]
Gemfibrozil	DMD8Q3J	Moderate	Decreased metabolism of Torasemide caused by Gemfibrozil mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[23]
Fenofibrate	DMFKXDY	Moderate	Decreased metabolism of Torasemide caused by Fenofibrate mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[23]
Etelcalcetide	DMHP9BL	Major	Increased risk of hypocalcemia by the combination of Torasemide and Etelcalcetide.	Hyper-parathyroidism [5A51]	[21]
Acebutolol	DM0TI4U	Moderate	Increased risk of ventricular arrhythmias by the combination of Torasemide and Acebutolol.	Hypertension [BA00-BA04]	[17]
Moexipril	DM26E4B	Moderate	Additive hypotensive effects by the combination of Torasemide and Moexipril.	Hypertension [BA00-BA04]	[40]
Bisoprolol	DM3UZ95	Moderate	Increased risk of hyperglycemia by the combination of Torasemide and Bisoprolol.	Hypertension [BA00-BA04]	[17]
Captopril	DM458UM	Moderate	Additive hypotensive effects by the combination of Torasemide and Captopril.	Hypertension [BA00-BA04]	[40]
Penbutolol	DM4ES8F	Moderate	Increased risk of ventricular arrhythmias by the combination of Torasemide and Penbutolol.	Hypertension [BA00-BA04]	[17]
Trandolapril	DM4L6EU	Moderate	Additive hypotensive effects by the combination of Torasemide and Trandolapril.	Hypertension [BA00-BA04]	[40]
Nebivolol	DM7F1PA	Moderate	Increased risk of ventricular arrhythmias by the combination of Torasemide and Nebivolol.	Hypertension [BA00-BA04]	[17]
Fosinopril	DM9NJ52	Moderate	Additive hypotensive effects by the combination of Torasemide and Fosinopril.	Hypertension [BA00-BA04]	[40]
Pindolol	DMD2NV7	Moderate	Increased risk of hypertriglyceridemia by the combination of Torasemide and Pindolol.	Hypertension [BA00-BA04]	[17]
Indapamide	DMGN1PW	Moderate	Increased risk of fluid/electrolyte loss by the combination of Torasemide and Indapamide.	Hypertension [BA00-BA04]	[18]
Benazepril	DMH1M9B	Moderate	Additive hypotensive effects by the combination of Torasemide and Benazepril.	Hypertension [BA00-BA04]	[40]
Trichlormethiazide	DMHAQCO	Moderate	Increased risk of fluid/electrolyte loss by the combination of Torasemide and Trichlormethiazide.	Hypertension [BA00-BA04]	[18]
Labetalol	DMK8U72	Moderate	Increased risk of hypertriglyceridemia by the combination of Torasemide and Labetalol.	Hypertension [BA00-BA04]	[17]
Enalapril	DMNFUZR	Moderate	Additive hypotensive effects by the combination of Torasemide and Enalapril.	Hypertension [BA00-BA04]	[40]
Atenolol	DMNKG1Z	Moderate	Increased risk of ventricular arrhythmias by the combination of Torasemide and Atenolol.	Hypertension [BA00-BA04]	[17]
Metoprolol	DMOJ0V6	Moderate	Increased risk of hypertriglyceridemia by the combination of Torasemide and Metoprolol.	Hypertension [BA00-BA04]	[17]
Quinapril	DMR8H31	Moderate	Additive hypotensive effects by the combination of Torasemide and Quinapril.	Hypertension [BA00-BA04]	[40]
Lisinopril	DMUOK4C	Moderate	Additive hypotensive effects by the combination of Torasemide and Lisinopril.	Hypertension [BA00-BA04]	[40]
Hydrochlorothiazide	DMUSZHD	Moderate	Increased risk of fluid/electrolyte loss by the combination of Torasemide and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[18]
Meclofenamic acid	DM05FXR	Moderate	Antagonize the effect of Torasemide when combined with Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[31]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Torasemide and Propiomazine.	Insomnia [7A00-7A0Z]	[28]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Torasemide and ITI-007.	Insomnia [7A00-7A0Z]	[28]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Torasemide caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[23]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Torasemide caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[25]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Torasemide and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[41]
Vemurafenib	DM62UG5	Moderate	Decreased metabolism of Torasemide caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[25]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Torasemide caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[21]
Nitisinone	DMVS9WQ	Moderate	Decreased metabolism of Torasemide caused by Nitisinone mediated inhibition of CYP450 enzyme.	Metabolism inborn error [5C50]	[23]
Propranolol	DM79NTF	Moderate	Increased risk of hypertriglyceridemia by the combination of Torasemide and Propranolol.	Migraine [8A80]	[17]
Pamidronate	DMB4AVP	Moderate	Increased risk of hypocalcemia by the combination of Torasemide and Pamidronate.	Mineral excesses [5B91]	[29]
Zoledronate	DMIXC7G	Moderate	Increased risk of hypocalcemia by the combination of Torasemide and Zoledronate.	Mineral excesses [5B91]	[29]
Ozanimod	DMT6AM2	Moderate	Additive hypotensive effects by the combination of Torasemide and Ozanimod.	Multiple sclerosis [8A40]	[26]
Methoxsalen	DME8FZ9	Moderate	Increased risk of photosensitivity reactions by the combination of Torasemide and Methoxsalen.	Mycosis fungoides [2B01]	[25]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Torasemide caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[23]
Droperidol	DM0DXA8	Major	Increased risk of ventricular arrhythmias by the combination of Torasemide and Droperidol.	Nausea/vomiting [MD90]	[42]
Prochlorperazine	DM53SRA	Moderate	Increased risk of ventricular arrhythmias by the combination of Torasemide and Prochlorperazine.	Nausea/vomiting [MD90]	[25]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Torasemide and Promethazine.	Nausea/vomiting [MD90]	[28]
Thiethylperazine	DMU3IET	Moderate	Additive hypotensive effects by the combination of Torasemide and Thiethylperazine.	Nausea/vomiting [MD90]	[28]
Sibutramine	DMFJTDI	Moderate	Increased risk of hyponatremia by the combination of Torasemide and Sibutramine.	Obesity [5B80-5B81]	[32]
Chlorthalidone	DM4DMBT	Moderate	Increased risk of fluid/electrolyte loss by the combination of Torasemide and Chlorthalidone.	Oedema [MG29]	[18]
Metolazone	DMB39LO	Moderate	Increased risk of fluid/electrolyte loss by the combination of Torasemide and Metolazone.	Oedema [MG29]	[18]
Polythiazide	DMCH80F	Moderate	Increased risk of fluid/electrolyte loss by the combination of Torasemide and Polythiazide.	Oedema [MG29]	[18]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of ventricular arrhythmias by the combination of Torasemide and Levomethadyl Acetate.	Opioid use disorder [6C43]	[43]
Rofecoxib	DM3P5DA	Moderate	Antagonize the effect of Torasemide when combined with Rofecoxib.	Osteoarthritis [FA00-FA05]	[31]
Valdecoxib	DMAY7H4	Moderate	Antagonize the effect of Torasemide when combined with Valdecoxib.	Osteoarthritis [FA00-FA05]	[31]
Diclofenac	DMPIHLS	Moderate	Antagonize the effect of Torasemide when combined with Diclofenac.	Osteoarthritis [FA00-FA05]	[31]
Naproxen	DMZ5RGV	Moderate	Antagonize the effect of Torasemide when combined with Naproxen.	Osteoarthritis [FA00-FA05]	[31]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Torasemide caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[23]
Carboplatin	DMG281S	Moderate	Increased risk of ototoxicity by the combination of Torasemide and Carboplatin.	Ovarian cancer [2C73]	[44]
Etodolac	DM6WJO9	Moderate	Antagonize the effect of Torasemide when combined with Etodolac.	Pain [MG30-MG3Z]	[31]
Diflunisal	DM7EN8I	Moderate	Antagonize the effect of Torasemide when combined with Diflunisal.	Pain [MG30-MG3Z]	[31]
Ibuprofen	DM8VCBE	Moderate	Antagonize the effect of Torasemide when combined with Ibuprofen.	Pain [MG30-MG3Z]	[31]
Nabumetone	DMAT2XH	Moderate	Antagonize the effect of Torasemide when combined with Nabumetone.	Pain [MG30-MG3Z]	[31]
Piroxicam	DMTK234	Moderate	Antagonize the effect of Torasemide when combined with Piroxicam.	Pain [MG30-MG3Z]	[31]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Torasemide and Safinamide.	Parkinsonism [8A00]	[26]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Torasemide and Rasagiline.	Parkinsonism [8A00]	[26]
Esomeprazole	DM7BN0X	Moderate	Increased risk of hypomagnesemia by the combination of Torasemide and Esomeprazole.	Peptic ulcer [DA61]	[27]
Ketorolac	DMI4EL5	Moderate	Antagonize the effect of Torasemide when combined with Ketorolac.	Postoperative inflammation [1A00-CA43]	[31]
Bromfenac	DMKB79O	Moderate	Antagonize the effect of Torasemide when combined with Bromfenac.	Postoperative inflammation [1A00-CA43]	[31]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Torasemide caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[23]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Torasemide caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[45]
Verteporfin	DMIY6DB	Moderate	Increased risk of photosensitivity reactions by the combination of Torasemide and Verteporfin.	Psoriasis [EA90]	[21]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Torasemide and Levomepromazine.	Psychotic disorder [6A20-6A25]	[28]
Fluphenazine	DMIT8LX	Moderate	Additive hypotensive effects by the combination of Torasemide and Fluphenazine.	Psychotic disorder [6A20-6A25]	[28]
Triflupromazine	DMKFQJP	Moderate	Increased risk of ventricular arrhythmias by the combination of Torasemide and Triflupromazine.	Psychotic disorder [6A20-6A25]	[25]
Sulfadiazine	DMTW3R8	Moderate	Decreased metabolism of Torasemide caused by Sulfadiazine mediated inhibition of CYP450 enzyme.	Rheumatic fever [1B40]	[23]
Meloxicam	DM2AR7L	Moderate	Antagonize the effect of Torasemide when combined with Meloxicam.	Rheumatoid arthritis [FA20]	[31]
Sulindac	DM2QHZU	Moderate	Antagonize the effect of Torasemide when combined with Sulindac.	Rheumatoid arthritis [FA20]	[31]
Celecoxib	DM6LOQU	Moderate	Antagonize the effect of Torasemide when combined with Celecoxib.	Rheumatoid arthritis [FA20]	[31]
Oxaprozin	DM9UB0P	Moderate	Antagonize the effect of Torasemide when combined with Oxaprozin.	Rheumatoid arthritis [FA20]	[31]
Flurbiprofen	DMGN4BY	Moderate	Antagonize the effect of Torasemide when combined with Flurbiprofen.	Rheumatoid arthritis [FA20]	[31]
Fenoprofen	DML5VQ0	Moderate	Antagonize the effect of Torasemide when combined with Fenoprofen.	Rheumatoid arthritis [FA20]	[31]
Leflunomide	DMR8ONJ	Moderate	Decreased metabolism of Torasemide caused by Leflunomide mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[23]
Indomethacin	DMSC4A7	Moderate	Antagonize the effect of Torasemide when combined with Indomethacin.	Rheumatoid arthritis [FA20]	[31]
Tolmetin	DMWUIJE	Moderate	Antagonize the effect of Torasemide when combined with Tolmetin.	Rheumatoid arthritis [FA20]	[31]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Torasemide and Quetiapine.	Schizophrenia [6A20]	[28]
Mesoridazine	DM2ZGAN	Moderate	Increased risk of ventricular arrhythmias by the combination of Torasemide and Mesoridazine.	Schizophrenia [6A20]	[25]
Thioridazine	DM35M8J	Moderate	Increased risk of ventricular arrhythmias by the combination of Torasemide and Thioridazine.	Schizophrenia [6A20]	[25]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Torasemide and Aripiprazole.	Schizophrenia [6A20]	[28]
Iloperidone	DM6AUFY	Moderate	Increased risk of ventricular arrhythmias by the combination of Torasemide and Iloperidone.	Schizophrenia [6A20]	[25]
Paliperidone	DM7NPJS	Moderate	Increased risk of ventricular arrhythmias by the combination of Torasemide and Paliperidone.	Schizophrenia [6A20]	[25]
Loxapine	DM8AI9U	Moderate	Additive hypotensive effects by the combination of Torasemide and Loxapine.	Schizophrenia [6A20]	[28]
Haloperidol	DM96SE0	Moderate	Increased risk of ventricular arrhythmias by the combination of Torasemide and Haloperidol.	Schizophrenia [6A20]	[25]
Perphenazine	DMA4MRX	Moderate	Increased risk of ventricular arrhythmias by the combination of Torasemide and Perphenazine.	Schizophrenia [6A20]	[25]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Torasemide and Molindone.	Schizophrenia [6A20]	[28]
Chlorpromazine	DMBGZI3	Moderate	Increased risk of ventricular arrhythmias by the combination of Torasemide and Chlorpromazine.	Schizophrenia [6A20]	[25]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Torasemide and Thiothixene.	Schizophrenia [6A20]	[28]
Clozapine	DMFC71L	Moderate	Additive hypotensive effects by the combination of Torasemide and Clozapine.	Schizophrenia [6A20]	[28]
Trifluoperazine	DMKBYWI	Moderate	Increased risk of ventricular arrhythmias by the combination of Torasemide and Trifluoperazine.	Schizophrenia [6A20]	[25]
Ziprasidone	DMM58JY	Major	Increased risk of ventricular arrhythmias by the combination of Torasemide and Ziprasidone.	Schizophrenia [6A20]	[46]
Risperidone	DMN6DXL	Moderate	Increased risk of ventricular arrhythmias by the combination of Torasemide and Risperidone.	Schizophrenia [6A20]	[25]
Olanzapine	DMPFN6Y	Moderate	Additive hypotensive effects by the combination of Torasemide and Olanzapine.	Schizophrenia [6A20]	[28]
Amisulpride	DMSJVAM	Moderate	Increased risk of ventricular arrhythmias by the combination of Torasemide and Amisulpride.	Schizophrenia [6A20]	[25]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Torasemide and Asenapine.	Schizophrenia [6A20]	[28]
Pimozide	DMW83TP	Major	Increased risk of ventricular arrhythmias by the combination of Torasemide and Pimozide.	Schizophrenia [6A20]	[37]
Cephapirin	DMV2JNY	Moderate	Increased renal excretion of Torasemide caused by Cephapirin.	Sepsis [1G40-1G41]	[20]
LDE225	DMM9F25	Moderate	Decreased metabolism of Torasemide caused by LDE225 mediated inhibition of CYP450 enzyme.	Skin cancer [2C30-2C37]	[23]
Cisplatin	DMRHGI9	Moderate	Increased risk of ototoxicity by the combination of Torasemide and Cisplatin.	Solid tumour/cancer [2A00-2F9Z]	[47]
Warfarin	DMJYCVW	Moderate	Decreased metabolism of Torasemide caused by Warfarin mediated inhibition of CYP450 enzyme.	Supraventricular tachyarrhythmia [BC81]	[21]
Clopidogrel	DMOL54H	Minor	Decreased metabolism of Torasemide caused by Clopidogrel mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[48]
Sulfamethizole	DMGCHDS	Moderate	Decreased metabolism of Torasemide caused by Sulfamethizole mediated inhibition of CYP450 enzyme.	Urinary tract infection [GC08]	[23]
Plazomicin	DMKMBES	Major	Increased risk of ototoxicity by the combination of Torasemide and Plazomicin.	Urinary tract infection [GC08]	[22]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Torasemide and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[28]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Torasemide and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[28]
Amiodarone	DMUTEX3	Major	Increased risk of ventricular arrhythmias by the combination of Torasemide and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[49]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Crospovidone	E00626	Not Available	Disintegrant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Torsemide 100 mg tablet	100 mg	Oral Tablet	Oral
Torsemide 5 mg tablet	5 mg	Oral Tablet	Oral
Torsemide 10 mg tablet	10 mg	Oral Tablet	Oral
Torsemide 20 mg tablet	20 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7312).
• [2] Comparative effects of furosemide and other diuretics in the treatment of heart failure: a systematic review and combined meta-analysis of randomized controlled trials. Heart Fail Rev. 2021 Jan;26(1):127-136.
• [3] Torsemide. 2023 Jul 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 JanC.
• [4] Wijnsma KL, Ter Heine R, Moes DJAR, Langemeijer S, Schols SEM, Volokhina EB, van den Heuvel LP, Wetzels JFM, van de Kar NCAJ, Bruggemann RJ: Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. Clin Pharmacokinet. 2019 Jul;58(7):859-874. doi: 10.1007/s40262-019-00742-8.
• [5] BDDCS applied to over 900 drugs
• [6] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [7] Indian Journal of Clinical Practice
• [8] A reappraisal of loop diuretic choice in heart failure patients. Am Heart J. 2015 Mar;169(3):323-33. doi: 10.1016/j.ahj.2014.12.009. Epub 2015 Jan 6.
• [9] Phillipps GH: Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med. 1990 Nov;84 Suppl A:19-23.
• [10] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [11] Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9.
• [12] Coleman J., Cox A. and Cowley N. (2011). Side Effects of Drugs Annual. Elsevier.
• [13] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [14] Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther. 2004 Dec;311(3):996-1007.
• [15] Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics. 1997 Feb;7(1):51-8. doi: 10.1097/00008571-199702000-00007.
• [16] Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium-potassium-chloride-cotransporter human variants hNKCC1A and hNKCC1B. Sci Rep. 2018 Jun 29;8(1):9877. doi: 10.1038/s41598-018-27995-w.
• [17] Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783]
• [18] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61. [PMID: 6701709]
• [19] Semple P, Tilstone WJ, Lawson DH "Furosemide and urinary digoxin clearance." N Engl J Med 293 (1975): 612-3. [PMID: 902451]
• [20] Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J "Pharmacokinetic interactions of ceftazidime and frusemide." J Chemother 7 Suppl (1995): 107-10. [PMID: 8904125]
• [21] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [22] Bates DE, Beaumont SJ, Baylis BW "Ototoxicity induced by gentamicin and furosemide." Ann Pharmacother 36 (2002): 446-51. [PMID: 11895059]
• [23] Miners JO, Rees DLP, Valente L, Veronese ME, Birkett DJ "Human hepatic cytochrome p450 2c9 catalyzes the rate-limiting pathway of torsemide metabolism." J Pharmacol Exp Ther 272 (1995): 1076-81. [PMID: 7891318]
• [24] Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
• [25] Cerner Multum, Inc. "Australian Product Information.".
• [26] Product Information. Marplan (isocarboxazid) Roche Laboratories, Nutley, NJ.
• [27] Product Information. Nexium (esomeprazole) Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [28] Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
• [29] Product Information. Skelid (tilundronate). Sanofi Winthrop Pharmaceuticals, New York, NY.
• [30] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32. [PMID: 9562227]
• [31] Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
• [32] Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
• [33] Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
• [34] Product Information. Diabinese (chlorpropamide). Pfizer US Pharmaceuticals, New York, NY.
• [35] Product Information. Aptiom (eslicarbazepine). Sunovion Pharmaceuticals Inc, Marlborough, MA.
• [36] Marone C, Muggli F, Lahn W, Frey FJ "Pharmacokinetic and pharmacodynamic interaction between furosemide and metolazone in man." Eur J Clin Invest 15 (1985): 253-7. [PMID: 3935455]
• [37] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57. [PMID: 10668858]
• [38] Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [39] Product Information. Kaletra (lopinavir-ritonavir) Abbott Pharmaceutical, Abbott Park, IL.
• [40] Murphy BF, Whitworth JA, Kincaid-Smith P "Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics." Br Med J 288 (1984): 844-5. [PMID: 6322905]
• [41] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [42] Canadian Pharmacists Association.
• [43] Cohen J "Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents." Am Heart J 122 (1991): 919-25. [PMID: 1678923]
• [44] Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O "Understanding platinum-induced ototoxicity." Trends Pharmacol Sci 34 (2013): 458-69. [PMID: 23769626]
• [45] Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
• [46] Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
• [47] Product Information. Edecrin (ethacrynic acid). Merck &amp Co, Inc, West Point, PA.
• [48] Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
• [49] Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]